GlycoNex Inc. is a Taiwan-based company principally engaged in the development and licensing of anti-cancer monoclonal antibodies, as well as the provision of carbohydrate antigen and protein drug related commission services. The Company is mainly involved in the development of anti-cancer monoclonal antibody new drugs and bio-similar drugs, as well as the licensing of monoclonal antibody targets and carbohydrate antigen and protein drug related services. The Company distributes its products in domestic market and to overseas markets, such as the rest areas of Asia.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
12/06/26	26.80 NT$	-3.42%	2,327,483
11/06/26	27.75 NT$	+9.90%	2,831,120
10/06/26	25.25 NT$	+0.60%	205,179
09/06/26	25.10 NT$	0.00%	173,457
08/06/26	25.10 NT$	-3.83%	321,439

End-of-day quote Taipei Exchange

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Taipei Exchange Other stock markets 11/06/2026			5-day change	1st Jan Change
27.75 ^TWD	+9.90%		+6.53%	+7.77%

05-14	GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-14	GlycoNex, Inc Receives PMDA Approval To Initiate First-In-Human Phase 1 Trial Of GNX1021 In Gastrointestinal Cancers	CI

Market Cap	3.02B 95.25M 82.66M 76.19M 71.39M 133M 9.12B 136M 909M 352M 4.4B 358M 350M 15.29B	P/E Ratio 2024	-11.8x	P/E Ratio 2025	-11.9x
Enterprise Value	2.8B 88.31M 76.64M 70.64M 66.19M 124M 8.46B 126M 843M 326M 4.08B 332M 324M 14.17B	EV / Sales 2024	154x	EV / Sales 2025	67.8x
Free-Float	80.91%	Yield 2024 *	-	Yield 2025	-

05-14	GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-14	GlycoNex, Inc Receives PMDA Approval To Initiate First-In-Human Phase 1 Trial Of GNX1021 In Gastrointestinal Cancers	CI
03-23	GlycoNex Inc. And Nippon Kayaku Co., Ltd. Enters Collaboration To Advance Next-Generation ADC Candidate	CI
03-13	GlycoNex Incorporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-08	GlycoNex Signs CDMO Service Agreement with Change Cure to Advance HMGB1-Targeted Antibody Program	CI
11-24	Glyconex, Inc. and Hokkaido University Hospital Launch Study to Advance Glycan-Directed ADC Development in Gastric Cancer	CI
11-14	GlycoNex Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
29/10/25	GlycoNex announces last patient dosed in phase 3 trial of SPD8, a denosumab biosimilar for osteoporosis	RE
29/10/25	GlycoNex, Inc. Announces Last Patient Dosed in Phase 3 Trial of SPD8, a Denosumab Biosimilar for Osteoporosis	CI
13/08/25	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
12/06/25	GlycoNex, Inc. Announces Publication of Preclinical Study on Gnx1021, A Novel Glycan-Targeted Adc for Gastric Cancer	CI
27/05/25	GlycoNex, Inc. Announces Publication of Research Involving Pro-Antibody, GNX201, in the International Journal of Biological Macromolecules	CI
12/05/25	GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2025	CI

1 day	+9.90%
1 week	+6.53%
Current month	+8.82%
1 month	+23.88%
3 months	+12.58%
6 months	+29.07%
Current year	+7.77%

GlycoNex Incorporation Share Price

Stocks

4168

TW0004168000

Biotechnology & Medical Research

Valuation: GlycoNex Incorporation

Chart: GlycoNex Incorporation

Latest news : GlycoNex Incorporation

Press Releases: GlycoNex Incorporation

Quotes and Performance

Course Extremes

Managers and Directors: GlycoNex Incorporation

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	24.65	27.75
1 month	22.3	29
Current year	22.1	30
1 year	20.55	30.95
3 years	15.6	33.2
5 years	15.6	46.9
10 years	10.2	46.9

Manager	Title	Age	Since
Mei Chun Yang CEO	Chief Executive Officer	-	31/12/2018
Dih Fen Wu DFI	Director of Finance/CFO	-	31/12/2009
Yao Hua Lue IRC	Investor Relations Contact	-	11/11/2012

Director	Title	Age	Since
Kao Chung Tsai BRD	Director/Board Member	64	-
Tong Hsuan Chang CHM	Chairman	-	31/01/2001
Ling-Chun Tsai BRD	Director/Board Member	-	24/05/2012

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GLYCONEX INCORPORATION	+9.90%	+6.53%	+9.68%	-9.02%	98.63M
LONZA GROUP AG	-0.77%	+0.49%	-16.35%	-13.14%	42.96B
REVOLUTION MEDICINES, INC.	+3.44%	+3.23%	+274.74%	+508.67%	31.73B
IQVIA HOLDINGS INC.	-0.89%	-2.44%	+12.47%	-15.54%	30.22B
BEONE MEDICINES AG	+2.07%	-2.00%	-4.28%	+24.15%	28.94B
CELLTRION, INC.	-0.66%	-5.84%	+7.59%	+12.76%	23.87B
MEDPACE HOLDINGS, INC.	-0.19%	+4.26%	+55.79%	+117.22%	13.57B
EUROFINS SCIENTIFIC SE	+0.06%	-0.89%	+6.49%	+8.03%	12.96B
ASCENDIS PHARMA A/S	+3.15%	+5.68%	-	-	13.39B
IONIS PHARMACEUTICALS, INC.	-0.14%	-0.61%	+107.82%	+77.82%	12.2B
Average	+1.64%	-1.16%	+50.44%	+79.00%	20.99B
Weighted average by Cap.	+0.68%	-2.39%	+53.96%	+95.41%

	2024	2025
Net sales	14.7M 464K 403K 371K 348K 650K 44.46M 664K 4.43M 1.72M 21.43M 1.74M 1.71M 74.52M	37.86M 1.2M 1.04M 957K 896K 1.67M 115M 1.71M 11.41M 4.42M 55.2M 4.49M 4.39M 192M
Net income	-230M -7.26M -6.3M -5.8M -5.44M -10.16M -695M -10.37M -69.23M -26.81M -335M -27.24M -26.65M -1.16B	-235M -7.43M -6.45M -5.94M -5.57M -10.41M -711M -10.62M -70.9M -27.45M -343M -27.89M -27.29M -1.19B
Net Debt	-442M -13.96M -12.12M -11.17M -10.47M -19.56M -1.34B -19.96M -133M -51.59M -645M -52.42M -51.29M -2.24B	-220M -6.94M -6.02M -5.55M -5.2M -9.72M -664M -9.92M -66.22M -25.64M -320M -26.05M -25.49M -1.11B